Abstract
Ketolides are semi-synthetic derivatives of Erythromycin A. Telithromycin is the first introduced in clinical practice. It was developed specifically for the treatment of community-acquired respiratory tract infections, since it demonstrates bacteriological efficiency against common and atypical respiratory pathogens, as well as good diffusion in respiratory tissues. It maintains efficacy against erythromycin resistant Gram-positive cocci and seems to not induce MLS B resistance. Telithromycin is available currently, but the other agents of this therapeutic class are not marketed yet.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have